Makary Resigns as FDA Commissioner Following Policy Disputes - Poll - MDSpire

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

  • By

  • Kathryn Wighton

  • May 12, 2026

  • 2 min

Share

Original Source(s)

Makary Resigns as FDA Commissioner Following Policy Disputes

  • by Kathryn Wighton

  • May 12, 2026

Related Content

GLP-1 Drugs Tied to Smell, Taste Changes

A matched electronic health record study of more than 876,000 patients with type 2 diabetes found a low absolute incidence but higher relative hazard of documented smell and taste disturbances among patients prescribed glucagon-like peptide-1 receptor agonists.

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.